|
WO2020115288A1
|
|
Biomarkers for cardiovascular events
|
|
EP3714273A1
|
|
Methods for prediction and early detection of diabetes
|
|
EP3649472A1
|
|
Methods for detecting ovarian cancer
|
|
EP3387446A2
|
|
Use of ceramides and lpls in diagnosing cvd
|
|
JP2016191718A
|
|
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
CA2959832A1
|
|
Methods for detecting ovarian cancer
|
|
US2015362513A1
|
|
Ceramides and their use in diagnosing CVD
|
|
CN105008931A
|
|
Non-high density lipoprotein derived CVD markers
|
|
EP2667197A1
|
|
Sensitive efficacy and specificity biomarkers for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
|
|
WO2012136856A1
|
|
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
EP2592422A1
|
|
Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
|
|
EP2592423A1
|
|
Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
|
|
EP2977764A1
|
|
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
CA2801459A1
|
|
Lipidomic biomarkers for identification of high-risk coronary artery disease patients
|
|
CN103502820A
|
|
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
EP2385374A1
|
|
Lipidomic biomarkers for atherosclerosis and cardiovascular disease
|
|
EP2064544A1
|
|
Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
|
|
WO2007144467A1
|
|
Diagnostic method for myopathy
|
|
CN101522910A
|
|
Diagnostic method for myopathy
|
